MarketBeat
25 Sept 2026, 03:02 UTC · 3h ago
Verdict
Headline takes no side. We score ARCT +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
Arcturus reported that LUNAR 2.0 produced 38-fold more OTC protein than the lipid used in ARCT-810 in primate studies.
Newpresented preliminary Phase II data
So whatThis potency leap could enable a dose reduction from 0.5 mg/kg to 0.3 mg/kg and reduce infusion time from 3 hours to 1 hour.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Preliminary Phase II data for ARCT-810 showed mean glutamine levels fell by 15% to 25% from pre-treatment levels.
Newpresented preliminary Phase II data
So whatPositive biomarker movement in a 10,000-patient target market supports the viability of the Phase II/III study planned for H2 2027.
More positive than 86% of claims this week
The company plans to integrate the next-gen ARCT-2601 into the existing ARCT-810 study by year-end.
Newpresented preliminary Phase II data
So whatThis pivot depends on GLP study results expected in November, creating a binary catalyst event next month.
More positive than 64% of claims this week
ARCT-810 was generally safe with no serious adverse events, though two participants experienced grade-three asymptomatic transaminitis.
Newpresented preliminary Phase II data
More positive than 52% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Positive Phase II data for ARCT-810 showing safety and efficacy in lowering ammonia/glutamine, combined with the introduction of a significantly more potent LUNAR 2.0 delivery platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
3h ago
—
ARCT hasn't traded since this ran. Last close $14.12 (Sep 24); the reaction starts at the next open.
ARCT chart →
